by CheckRare Staff | Oct 29, 2025
Accurate diagnosis and treatment of epilepsy challenges the medical community, patients, and their loved ones.[1] As many as one third of patients have seizures that are inadequately controlled with available therapies, and treatment response is highly variable.[2,3]...
by CheckRare Staff | Oct 21, 2025
A Spotlight on Two Main Subtypes: Mycosis Fungoides and Sézary Syndrome Cutaneous T-cell lymphoma (CTCL) belongs to the non-Hodgkin lymphoma class of hematologic T-cell lymphoproliferative disorders.[1] Cutaneous T-cell lymphoma is a rare group of malignancies,...
by CheckRare Staff | Oct 9, 2025
Watch the DAYBUE® (trofinetide) in Practice Video Series to Hear Expert Insights on the First Treatment for This Rare Disease By: CheckRare Staff | Updated on: Jan 28, 2025 Rett syndrome thought leaders discuss how DAYBUE® (trofinetide), the first and only...
by CheckRare Staff | Oct 3, 2025
Jacky Smith, MB, ChB, FRCP, PhD, Chair of Respiratory Medicine at the University of Manchester, discusses topline results from the phase 2a RIVER trial for patients with refractory chronic cough (RCC). Topline results and a responder analysis from the RIVER...
by CheckRare Staff | Sep 3, 2025
Survey Finds Wide-Ranging Impact of X-Linked Hypophosphatemia (XLH) on Patient Experiences Findings highlight the burden of XLH on personal finances and out-of-pocket costs, overall health—physical, mental, and social—and access to expert care. XLH Community...
